Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

ASCO’s updated guidelines for advanced ovarian cancer emphasize health equity and provide new recommendations for HIPEC while ...

A new clinical trial from Scripps Research in La Jolla aims to make significant gains in the global fight against malaria by ...

The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake.

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Dogs of the Dow can be described as the 10 highest yielding stocks that are within the DJI. Read more to see the best Dog of ...

Excerpts from recent editorials in the United States and abroad: ___ Feb. 20 The Washington Post says Musk's mass firings are backfiring President Donald Trump and Elon Musk have been rapidly firing ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Glenmark Pharmaceuticals on Monday said it will pay USD 7 million to three entities to settle lawsuits in the US related to ...

Glenmark Pharmaceuticals will pay USD 7 million to settle lawsuits in the US related to generic drugs, including Zetia and ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.